胆酸对从轻度认知障碍到痴呆症的进展的影响:使用共同数据模型对多中心韩国数据库的分布式网络分析
Jung-Min Pyun1, Inho Lee2, Kyungbok Lee1
1Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
Dementia and neurocognitive disorders
|November 8, 2024
概括
在这项研究中,胆醇酸盐 (CA) 没有显著影响防止从轻度认知障碍 (MCI) 到痴呆症的进展. 需要进一步的研究来探索特定患者子组的潜在益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 胆醇酸盐 (CA) 以其在阿尔茨海默氏症痴呆症 (ADD) 中的认知益处而闻名.
- 关于CA对轻度认知障碍 (MCI) 进展的影响的证据有限.
- 现实世界的数据对于理解CA在MCI中的作用至关重要.
研究的目的:
- 评估胆醇酸盐 (CA) 对从轻度认知障碍 (MCI) 到全因痴呆症或阿尔茨海默氏症痴呆症 (ADD) 的进展的影响.
- 通过使用共同数据模型 (CDM) 来分析来自韩国观测数据库的真实世界数据.
主要方法:
- 包括60岁以上被诊断患有MCI的患者.
- 倾向性得分匹配产生3062匹配的CA用户和非用户对.
- 考克斯回归分析以确定MCI进展的危险比率 (HR),根据性别,乙胆酶抑制剂 (AchEI) 使用和多尼佩西尔使用进行子组分析.
主要成果:
- 在三家医院进行的元分析显示,CA使用与从MCI发展为所有原因痴呆症之间没有显著的关联 (HR,0.93;95%CI,0.59-1.26).
- 同时,CA使用与ADD的进展无关 (HR,1.05;95%CI,0.51-1.59).
- 亚组分析证实,在不同的人口和治疗群体中,CA使用和MCI进展之间没有关系.
结论:
- 这项使用真实世界数据的多中心队列研究发现,胆二酸盐 (CA) 使用与从MCI发展为全因痴呆或ADD之间没有关联.
- 这些发现表明,CA可能无法有效地预防MCI患者的痴呆转化.
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:30Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98